Local delivery of an antithrombin inhibits platelet-dependent thrombosis

• Published in: Circulation (New York, N.Y.) Vol. 90; no. 4; pp. 1951 - 1955
• Main Authors: Scott, N A, Nunes, G L, King, 3rd, S B, Harker, L A, Hanson, S R
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01-10-1994
• Subjects: Amino Acid Chloromethyl Ketones - administration & dosage; Amino Acid Chloromethyl Ketones - pharmacology; Animals; Antithrombins - administration & dosage; Antithrombins - pharmacology; Blood Platelets - drug effects; Blood Platelets - physiology; Blood Vessel Prosthesis; Coronary Thrombosis - prevention & control; Dose-Response Relationship, Drug; Hemostasis - drug effects; Injections, Intravenous; Polyethylene Terephthalates; Swine
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.90.4.1951

Platelet-dependent thrombosis can be effectively inhibited by intravenous administration of direct thrombin antagonists. However, an increased propensity for abnormal bleeding has been associated with systemic administration of these agents. The goal of this study was to determine whether local delivery of a potent thrombin inhibitor, D-Phe-L-Pro-L-Arg chloromethyl ketone (PPACK), could inhibit platelet-dependent thrombosis without altering systemic hemostatic function.
Thrombus formation was measured by quantitative imaging of 111In-labeled platelet deposition on segments of thrombogenic vascular graft interposed in arteriovenous shunts in a porcine model. Intravenous administration of PPACK inhibited platelet deposition at a dose of 12.5 micrograms/kg per minute, which was associated with significant prolongations of both template bleeding times and activated partial thromboplastin times. By contrast, local infusion of PPACK at a dose of 0.02 micrograms/kg per minute (ie, a 600-fold smaller dose) into the fluid boundary layer at the interface between flowing blood and the thrombogenic segment produced equivalent inhibition of platelet deposition without prolonging either the bleeding time or the activated partial thromboplastin time. In addition, static exposure of a mural thrombus to solutions of PPACK at concentrations > or = 2.5 mg/mL for 15 minutes produced sustained inhibition of platelet-dependent thrombosis with no change in hemostatic measurements.
These results indicate that local delivery of the direct antithrombin PPACK, by either boundary layer infusion or static application techniques, effectively inhibits platelet-dependent thrombosis at doses that are several orders of magnitude less than the systemic dose required for an equivalent antithrombotic effect. In contrast to the systemic administration of PPACK, local delivery produced maximal inhibition of thrombosis without alterations in hemostasis.